CoChat
Sign Up
Cited by 366

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Brain atrophy in clinically early relapsing–remitting multiple sclerosis

Chard, D. T., Griffin, C. M., Parker, G. J. M., Kapoor, R., Thompson, A. J., Miller, D. H.·2002·Brain
DOI 10.1093/brain/awf025
Open this paper in CoChat — free account

Abstract

Brain atrophy measured by MRI is a potentially useful tool for monitoring disease progression in multiple sclerosis. The location, extent and mechanisms of brain atrophy in early disease are not well documented. Using quantitative MRI, this study investigated whole brain, grey and white matter atrophy in clinically early relapsing-remitting multiple sclerosis and its relationship to lesion measures. Data came from 27 normal control subjects (14 females and 13 males, mean age 36.1 years) and 26 subjects with clinically definite multiple sclerosis (18 females and eight males, mean age 35.1 years, mean delay from first symptom to scan 1.8 years, median Expanded Disability Status Scale score 1.0). All had three-dimensional fast spoiled gradient recall (3D FSPGR), T(1)-weighted pre- and post-gadolinium-enhanced and T(2)-weighted scans. The 3D FSPGR images were automatically segmented into grey and white matter and cerebrospinal fluid using SPM99. 3D FSPGR hypo-intense, T(2) hyper-intense, T(1) hypo-intense and T(1) post-gadolinium-enhancing lesion volumes were determined by semi-automatic lesion segmentation. The SPM99 output was combined with the 3D FSPGR lesion segmentations to quantify tissue volumes as fractions of total intracranial volumes, producing values for the brain parenchymal fraction (BPF), white matter fraction (WMF) and grey matter fraction (GMF). Comparing multiple sclerosis with control subjects, BPF, GMF and WMF were significantly reduced (P < 0.001 for all tiss…

Overview

Integrity signals

Registry

Crossref · 10.1093/brain/awf025

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Show all 3 references

Research works printed but not linked: 51

  1. Allen IV, McKeown SR. A histological, histochemical and biochemical study of the macroscopically normal white matter in multiple sclerosis. J Neurol Sci1979; 41: 81–91. · DOI
  2. Ashburner J, Friston K. Multimodal image coregistration and partitioning—a unified framework. Neuroimage1997; 6: 209–17. · DOI
  3. Ashburner J, Friston KJ. Voxel‐based morphometry—the methods. [Review]. Neuroimage2000; 11: 805–21. · DOI · Paper page
  4. Blatter DD, Bigler ED, Gale SD, Johnson SC, Anderson CV, Burnett BM, et al. Quantitative volumetric analysis of brain MR: normative database spanning 5 decades of life. AJNR Am J Neuroradiol1995; 16: 241–51.
  5. Brex PA, Jenkins R, Fox NC, Crum WR, O’Riordan JI, Plant GT, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology2000; 54: 1689–91. · DOI
  6. Brownell B, Hughes JT. The distribution of plaques in the cerebrum in multiple sclerosis. J Neurol Neurosurg Psychiatry1962; 25: 315–20. · DOI
  7. Bruck W, Bitsch A, Kolenda H, Bruck Y, Stiefel M, Lassmann H. Inflammatory central nervous system demyelination: correlation of magnetic resonance imaging findings with lesion pathology. Ann Neurol1997; 42: 783–93. · DOI
  8. Brunetti A, Postiglione A, Tedeschi E, Ciarmiello A, Quarantelli M, Covelli EM, et al. Measurement of global brain atrophy in Alzheimer’s disease with unsupervised segmentation of spin‐echo MRI studies. J Magn Reson Imaging2000; 11: 260–6. · DOI
  9. Chard DT, Parker GJM, Griffin CMB, Thompson AJ, Miller DH. Age and gender effects on brain grey and white matter volumes in normal controls: the reproducibility and sensitivity of an SPM based segmentation methodology [abstract]. Proc Soc Magn Reson Med2001; 9: 1377.
  10. Coffey CE, Lucke JF, Saxton JA, Ratcliff G, Unitas LJ, Billig B, et al. Sex differences in brain aging: a quantitative magnetic resonance imaging study. Arch Neurol1998; 55: 169–79. · DOI
  11. Coles AJ, Wing MG, Molyneux P, Paolillo A, Davie CM, Hale G, et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol1999; 46: 296–304. · DOI
  12. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain1997; 120: 393–9. · DOI · Paper page
  13. Filippi M, Rocca MA, Horsfield MA, Rovaris M, Pereira C, Yousry TA, et al. Increased spatial resolution using a three‐dimensional T1‐weighted gradient‐echo MR sequence results in greater hypointense lesion volumes in multiple sclerosis. AJNR Am J Neuroradiol1998; 19: 235–8.
  14. Fox NC, Jenkins R, Leary SM, Stevenson VL, Losseff NA, Crum WR, et al. Progressive cerebral atrophy in MS: a serial study using registered, volumetric MRI. Neurology2000; 54: 807–12. · DOI
  15. Ge Y, Grossman RI, Udupa JK, Wei L, Mannon LJ, Polansky M, et al. Brain atrophy in relapsing‐remitting multiple sclerosis and secondary progressive multiple sclerosis: longitudinal quantitative analysis. Radiology2000; 214: 665–70. · DOI
  16. Harris JO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium‐enhanced magnetic resonance imaging scans in patients with early, relapsing–remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol1991; 29: 548–55. · DOI
  17. Harris GJ, Schlaepfer TE, Peng LW, Lee S, Federman EB, Pearlson GD. Magnetic resonance imaging evaluation of the effects of ageing on grey‐white ratio in the human brain. Neuropathol Appl Neurobiol1994; 20: 290–3. · DOI
  18. Jenkins R, Fox NC, Rossor AM, Harvey RJ, Rossor MN. Intracranial volume and Alzheimer disease: evidence against the cerebral reserve hypothesis. Arch Neurol2000; 57: 220–4. · DOI
  19. Kapeller P, Mclean MA, Griffin CM, Chard D, Parker GJ, Barker GJ, et al. Preliminary evidence for neuronal damage in cortical grey matter and normal appearing white matter in short duration relapsing–remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol2001; 248: 131–8. · DOI
  20. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol1993; 34: 661–9. · DOI · Paper page
  21. Kidd D, Barkhof F, McConnell R, Algra PR, Allen IV, Revesz T. Cortical lesions in multiple sclerosis. Brain1999; 122: 17–26. · DOI · Paper page
  22. Kornek B, Storch MK, Weissert R, Wallstroem E, Stefferl A, Olsson T, et al. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol2000; 157: 267–76. · DOI
  23. Lim KO, Zipursky RB, Watts MC, Pfefferbaum A. Decreased gray matter in normal aging: an in vivo magnetic resonance study. J Gerontol1992; 47: B26–30. · DOI
  24. Liu C, Edwards S, Gong Q, Roberts N, Blumhardt LD. Three dimensional MRI estimates of brain and spinal cord atrophy in multiple sclerosis. J Neurol Neurosurg Psychiatry1999; 66: 323–30. · DOI
  25. Losseff NA, Wang L, Lai HM, Yoo DS, Gawne‐Cain ML, McDonald WI, et al. Progressive cerebral atrophy in multiple sclerosis. A serial MRI study. Brain1996; 119: 2009–19. · DOI
  26. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–11. · DOI
  27. Luks TL, Goodkin DE, Nelson SJ, Majumdar S, Bacchetti P, Portnoy D, et al. A longitudinal study of ventricular volume in early relapsing–remitting multiple sclerosis. Mult Scler2000; 6: 332–7. · DOI
  28. Mader I, Roser W, Kappos L, Hagberg G, Seelig J, Radue EW, et al. Serial proton MR spectroscopy of contrast‐enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol2000; 21: 1220–7.
  29. Miller AK, Alston RL, Corsellis JA. Variation with age in the volumes of grey and white matter in the cerebral hemispheres of man: measurements with an image analyser. Neuropathol Appl Neurobiol1980; 6: 119–32. · DOI
  30. Molyneux PD, Tubridy N, Parker GJ, Barker GJ, MacManus DG, Tofts PS, et al. The effect of section thickness on MR lesion detection and quantification in multiple sclerosis. AJNR Am J Neuroradiol1998; 19: 1715–20.
  31. Molyneux PD, Kappos L, Polman C, Pozzilli C, Barkhof F, Filippi M, et al. The effect of interferon beta‐1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain2000; 123: 2256–63. · DOI
  32. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast‐enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol1998; 43: 56–71. · DOI
  33. Pakkenberg B, Gundersen HJ. Neocortical neuron number in humans: effect of sex and age. J Comp Neurol 1997; 384: 312–20. · DOI
  34. Paolillo A, Pozzilli C, Gasperini C, Giugni E, Mainero C, Giuliani S, et al. Brain atrophy in relapsing‐remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability. J Neurol Sci2000; 174: 85–91. · DOI
  35. Passe TJ, Rajagopalan P, Tupler LA, Byrum CE, MacFall JR, Krishnan KR. Age and sex effects on brain morphology. Prog Neuropsychopharmacol Biol Psychiatry1997; 21: 1231–7. · DOI
  36. Pfefferbaum A, Mathalon DH, Sullivan EV, Rawles JM, Zipursky RB, Lim KO. A quantitative magnetic resonance imaging study of changes in brain morphology from infancy to late adulthood. Arch Neurol1994; 51: 874–87. · DOI · Paper page
  37. Plummer DL. Dispimage: a display and analysis tool for medical images. Rev Neuroradiol1992; 5: 489–95. · DOI
  38. Poser CM, Paty DW, Scheinberg L, MacDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol1983; 13: 227–31. · DOI · Paper page
  39. Prineas JW, Connell F. The fine structure of chronically active multiple sclerosis plaques. Neurology 1978; 28: 68–75. · DOI
  40. Rovaris M, Rocca MA, Sormani MP, Comi G, Filippi M. Reproducibility of brain MRI lesion volume measurements in multiple sclerosis using a local thresholding technique: effects of formal operator training. Eur Neurol1999; 41: 226–30. · DOI
  41. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing–remitting MS. Multiple Sclerosis Collaborative Research Group. Neurology1999; 53: 1698–704. · DOI
  42. Saindane AM, Ge Y, Udupa JK, Babb JS, Mannon LJ, Grossman RI. The effect of gadolinium‐enhancing lesions on whole brain atrophy in relapsing–remitting MS. Neurology2000; 55: 61–5. · DOI
  43. Shah M, Ross JS, VanDyke C, Rudick RA, Goodkin DE, Obuchowski N, et al. Volume T1‐weighted gradient echo MRI in multiple sclerosis patients. J Comput Assist Tomogr1992; 16: 731–6. · DOI
  44. Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, et al. A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology1999; 53: 139–48. · DOI
  45. Simon JH, Kinkel RP, Jacobs L, Bub L, Simonian N. A Wallerian degeneration pattern in patients at risk for MS. Neurology2000; 54: 1155–60. · DOI
  46. Stevenson VL, Miller DH, Leary SM, Rovaris M, Barkhof F, Brochet B, et al. One year follow up study of primary and transitional progressive multiple sclerosis. J Neurol Neurosurg Psychiatry2000; 68: 713–18. · DOI
  47. Thompson AJ, Kermode AG, Wicks D, MacManus DG, Kendall BE, Kingsley DP, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol1991; 29: 53–62. · DOI
  48. Tourtellotte WW, Parker JA. Some spaces and barriers in postmortem multiple sclerosis. Prog Brain Res1968; 29: 493–525. · DOI
  49. van Walderveen MA, Kamphorst W, Scheltens P, van Waesberghe JH, Ravid R, Valk J, et al. Histopathologic correlate of hypointense lesions on T1‐weighted spin‐echo MRI in multiple sclerosis. Neurology1998; 50: 1282–8. · DOI · Paper page
  50. Xu J, Kobayashi S, Yamaguchi S, Iijima K, Okada K, Yamashita K. Gender effects on age‐related changes in brain structure. AJNR Am J Neuroradiol2000; 21: 112–18.
  51. Yin X, Crawford TO, Griffin JW, Tu Ph, Lee VM, Li C, et al. Myelin‐associated glycoprotein is a myelin signal that modulates the caliber of myelinated axons. [Review]. J Neurosci1998; 18: 1953–62. · DOI

Cited by

Sorted by citations

See all 366

Metadata

Authors
Chard, D. T., Griffin, C. M., Parker, G. J. M., Kapoor, R., Thompson, A. J., & Miller, D. H.
Venue
Brain
Publisher
Oxford University Press (OUP)
Published
2002-02-01
Volume
125
Issue
2
Pages
327-337
ISSN
  • 1460-2156
  • 0006-8950
DOI
10.1093/brain/awf025
Cited by
366
References
3
Language
en

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review